ArticleHead & neck2014

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

J Hun Hah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.